Form 4: Quest Diagnostics CEO Sells Shares

Quest Diagnostics CEO and President J. E. Davis sold a total of 12,968 shares of common stock on March 2, 2026, including sales for tax obligations and under a 10b5-1 plan.

Summary

• J. E. Davis, CEO and President of Quest Diagnostics Inc. (DGX), reported two sales of common stock on March 2, 2026.
• One transaction involved the disposition of 2,968 shares at a price of $204.86 per share to satisfy tax obligations arising from the vesting of previously granted restricted share units.
• A second transaction involved the sale of 10,000 shares at a price of $212.52 per share, which was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
• Following these reported transactions, J. E. Davis beneficially owns 117,185 shares of Quest Diagnostics common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the insider selling, although the presence of a 10b5-1 plan for a portion of the sale suggests a pre-planned disposition rather than an immediate reaction to new information.

Negatives

• The CEO and President sold a total of 12,968 shares of common stock, which can be interpreted by some investors as a negative signal, despite the stated reasons for the sales.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, particularly when related to tax obligations from equity vesting or executed under a pre-arranged 10b5-1 plan, is a routine disclosure for executives managing their equity compensation and personal finances. Such transactions are common across the healthcare diagnostics industry as executives monetize vested stock awards.

Stakeholder Impact

• Shareholders may interpret the insider selling as a slight negative signal regarding management's confidence in the company's near-term prospects, despite the routine nature of some of the transactions.

Key Dates

Recommendation

The insider selling, while partly for tax obligations and partly pre-planned under a 10b5-1, represents a reduction in the CEO's direct holdings. This is not a strong positive signal, but also not an alarming sell-off, warranting a 'hold' as other fundamental factors would likely outweigh this single transaction in an investment decision.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Equity Compensation